Understanding neurodiversity: What every parent and pediatrician should know when it comes to your child’s brain development
Parents and pediatricians navigate the complexities of neurodiversity, emphasizing the need for open communication and better resources for child development.
Weekly review: Berdazimer gel launch, rise in US measles cases, and more
Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
FDA approves gardenia blue as natural color additive for food use
The FDA approves gardenia (genipin) blue as a natural food color, enhancing options for manufacturers and supporting the shift away from synthetic dyes.
Neonatal deaths in the US decline overall, but malnutrition-related mortality rises
A study reveals declining US neonatal mortality overall, yet highlights rising deaths from fetal malnutrition, emphasizing ongoing disparities in neonatal health outcomes.
Consumer wearables predict postoperative complications in children undergoing appendectomy
Wearable-derived biorhythms predicted postoperative complications in children up to 3 days early, offering a new tool for remote pediatric monitoring.
FDA-approved berdazimer gel, 10.3% launches to treat molluscum contagiosum
The nitric oxide–releasing topical is the first prescription medication approved for at-home treatment of molluscum contagiosum.
Cannabidiol demonstrates safety, mixed efficacy for severe behavior problems in autistic boys
A clinical trial found CBD was safe and well-tolerated in autistic boys, with some showing behavioral improvements, though placebo effects were strong.
Summer camp: A beacon of hope and healing for families with childhood cancer survivors
Cancer-specific summer camps empower children with cancer, fostering community, emotional healing, and safe fun, while providing families much-needed respite and support.
Lead exposure in early childhood linked to faster memory loss
Even low-level lead exposure in early childhood may speed up memory loss, according to a new study using a cognitive task to measure forgetting rates.
Pro-inflammatory diet during pregnancy tied to diabetes in children
A pro-inflammatory maternal diet during pregnancy was linked to a 16% higher risk of type 1 diabetes in offspring, Danish cohort study finds.
An 11-year-old boy with a petechial rash: A peculiar presentation
His vital signs in clinic were within normal limits, and the only additional finding at this time was a nontender, nonpruritic, and nonpalpable petechial rash on the bilateral lower extremities.
Can you diagnose this 11-year-old with a petechial rash?
Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.
Specific groups with chronic conditions who could most benefit from RSV prophylaxis
A newly-published study identified specific groups of higher-risk children that could benefit most from monoclonal antibodies.
FDA accepts NDA for ET-600, desmopressin oral solution for pediatric AVP deficiency
The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.
US measles cases reach new record high since eradication declaration in 2000
A week into July 2025, the total reported cases in the United States have surpassed the peak of 1274 cases recorded for all 2019.
FDA approves sebetralstat as first and only on-demand treatment for HAE
Though the original target action date was not met by the FDA, KalVista's sebetralstat is now approved to treat HAE in patients 12 years and older.
Weekly review: Label changes to maralixibat, pediatric mental health data, and more
Key FDA approvals in pediatric health: First half of 2025
A roundup of the most impactful FDA approvals in pediatric health from January through June 2025, spanning diagnostics, therapeutics, and at-home care.
Advancing pediatric health: Key updates and clinical insights from the first half of 2025
A look back at the most important FDA approvals, clinical research, and expert perspectives shaping pediatric health care in the first half of 2025.
AAP tips: How to keep kids safe around fireworks this summer
The American Academy of Pediatrics warns families to avoid home fireworks and offers safer alternatives to prevent injuries, especially in young children.
Q2 2025: A recap of the top headlines and interviews
View our Q2 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.
Long sleep duration after acute concussion in youths associated with more symptoms later
Additionally, long sleep duration could be associated with increased odds of being reliably symptomatic at 4 weeks.
Study: Idiopathic central precocious puberty patients at increased risk for psychiatric disorders
Data from the study suggest caretakers of CPP patients be vigilant for psychiatric symptoms to begin care at an early stage.
Top 5 pediatric health headlines you missed in June 2025
Take a quick look at everything you may have missed last month, including the top FDA approvals and latest clinical updates.
FDA revises labeling on extended-release stimulants for ADHD to include weight loss risk
The revised labeling will warn that patients younger than 6 years taking these medications are at greater risk of weight loss.
FDA news in pediatrics: June 2025
A look back at the FDA submissions and regulatory decisions in the pediatric health care space from June 2025.
FDA notifies providers of safety-related changes to prescribing information of maralixibat, odevixibat
The updated labeling includes a new contraindication for patients with prior or active hepatic events.
MNV-201 receives fast track, rare pediatric disease to treat Pearson Syndrome
MNV-201 is being evaluated in phase 2 clinical trials for treatment of the ultra-rare, life-threatening mitochondrial disorder affecting children.
New 2022 data: Pediatric mental health hospitalizations decline overall, increase for females
The total number of pediatric mental health hospitalizations declined in 2022, the first time observed since 2009.
Weekly review: ACIP meets and votes, marstacimab data for hemophilia, and more
